The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study

MLA

Rubina M. Khair, et al. “The Impact of Ambrisentan and Tadalafil Upfront Combination Therapy on Cardiac Function in Scleroderma Associated Pulmonary Arterial Hypertension Patients: Cardiac Magnetic Resonance Feature Tracking Study.” Pulmonary Circulation, vol. 8, Jan. 2018, pp. 1–11. EBSCOhost, https://doi.org/10.1177/2045893217748307.

APA

Rubina M. Khair, Stefan L. Zimmerman, Celia P. Corona-Villalobos, Erica H. Pullins, Reda E. Girgis, Ryan J. Tedford, Todd M. Kolb, Takahiro Sato, Joao A.C. Lima, Stephen C. Mathai, Rachel L. Damico, Paul M. Hassoun, Roham T. Zamanian, Bharath Ambale-Venkatesh, Olivia L. Hulme, Omar A. Minai, Kelly Chin, & Tomoki Fujii. (2018). The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study. Pulmonary Circulation, 8, 1–11. https://doi.org/10.1177/2045893217748307

Chicago

Rubina M. Khair, Stefan L. Zimmerman, Celia P. Corona-Villalobos, Erica H. Pullins, Reda E. Girgis, Ryan J. Tedford, Todd M. Kolb, et al. 2018. “The Impact of Ambrisentan and Tadalafil Upfront Combination Therapy on Cardiac Function in Scleroderma Associated Pulmonary Arterial Hypertension Patients: Cardiac Magnetic Resonance Feature Tracking Study.” Pulmonary Circulation 8 (January): 1–11. doi:10.1177/2045893217748307.